Financial Contrast: Sintx Technologies (NASDAQ:SINT) vs. Quoin Pharmaceuticals (NASDAQ:QNRX) – Defense World
Posted by admin on Jun 4th, 2022
Sintx Technologies (NASDAQ:SINT – Get Rating) and Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
Risk and Volatility
Sintx Technologies has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Valuation & Earnings
This table compares Sintx Technologies and Quoin Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
Sintx Technologies has higher revenue and earnings than Quoin Pharmaceuticals.
Institutional and Insider Ownership
6.7% of Sintx Technologies shares are owned by institutional investors. Comparatively, 21.7% of Quoin Pharmaceuticals shares are owned by institutional investors. 0.8% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Sintx Technologies and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.
Analyst Recommendations
This is a breakdown of recent recommendations for Sintx Technologies and Quoin Pharmaceuticals, as reported by MarketBeat.
Sintx Technologies presently has a consensus target price of $2.75, indicating a potential upside of 480.90%. Quoin Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 550.41%. Given Quoin Pharmaceuticals’ higher probable upside, analysts clearly believe Quoin Pharmaceuticals is more favorable than Sintx Technologies.
Sintx Technologies Company Profile (Get Rating)
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Quoin Pharmaceuticals Company Profile (Get Rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Receive News & Ratings for Sintx Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sintx Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
Analyzing Spok (SPOK) & Its Competitors
Critical Analysis: International Game Technology (NYSE:IGT) versus Super Group (NYSE:SGHC)